Related Experiment Video
Updated: May 1, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Should we still prescribe digoxin in mild-to-moderate heart failure? Is quality of life the issue rather than
J Soler-Soler1, G Permanyer-Miralda
1Servicio de Cardiología, Hospital General Universitari Vall d'Hebron, Barcelona, Spain.
Insights
Digoxin does not improve survival in heart failure but may help with symptoms. This study suggests digoxin offers symptomatic improvement for mild to moderate heart failure patients, though effects are modest.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- The Digitalis Investigation Group (DIG) study found digoxin does not improve heart failure survival.
- However, its role in symptomatic improvement for mild to moderate heart failure remains a key clinical question.
Purpose of the Study:
- To evaluate the efficacy of digoxin for symptomatic improvement in patients with mild to moderate heart failure.
- To address the lack of precise clinical measures for categorizing heart failure severity.
Main Methods:
- Analysis of data from multiple clinical trials, including the DIG study and others like the Randomized Assessment of the effect of Digoxin on Inhibitors of ACE Study.
- Utilizing subgroup analyses and direct clinical measures of patient outcomes.
Main Results:
- Digoxin demonstrated a beneficial clinical effect, particularly in subgroups with less severe heart failure.
- Other trials using direct clinical measures indicated definite symptomatic improvement in patients on digoxin therapy for mild heart failure.
- The magnitude of symptomatic benefit from digoxin therapy was generally modest.
Conclusions:
- Digoxin can be considered effective for symptomatic improvement in patients with mild to moderate heart failure.
- Despite modest effects and some safety concerns, its use for symptom management is supported.
- Physician discretion is advised for initiating digoxin therapy due to the small effect size.
Abstract:
The recently reported Digitalis Investigation Group (DIG) study has shown that digoxin has no demonstrable effect on survival in heart failure, but may be useful to ameliorate morbidity. The question may be raised whether digoxin is useful for symptomatic improvement in patients with mild or moderate heart failure. A major difficulty in answering this question is the lack of appropriate clinical measures of heart failure that allow a categorization such as mild, moderate and severe heart failure. However, data in several clinical trials permit an approach to this issue in an approximate way. For instance, the DIG study itself indicated that the beneficial clinical effect of digoxin was also apparent in pre-defined subgroups which corresponded to less severe forms of heart failure. The problem with the DIG study in this respect was the lack of direct measures of clinical improvement and the use of what might be taken as surrogates for these; however, it can probably be assumed that digoxin had a beneficial symptomatic effect even in patients with milder forms of heart failure. Direct clinical measures of clinical result were used in the Randomized Assessment of the effect of Digoxin on Inhibitors of ACE Study and the Prospective Randomized Study on Ventricular Failure and the Efficacy of Digoxin. Some inconsistencies between the clinical results of these trials may be explained partly on the basis of sample size, although on the whole the results point to a definite clinical improvement of patients on digoxin therapy, even when heart failure was considered to be mild on the basis of several measurements. Admittedly, the size of the effect of digoxin therapy in these patients may be quite modest. Although some concerns over safety may remain after the DIG trial, it can generally be accepted that digoxin is an effective drug for symptomatic improvement in patients with mild or moderate heart failure. The small size of this effect, however, indicates that the decision to use the drug may well be left to the discretion of the attending physician.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Diuretics
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

